Empagliflozin improves clinical outcomes for patients hospitalized with acute heart failure
In short: Researchers who conducted a multinational randomized trial found that the drug empagliflozin provides significant clinical benefits for patients hospitalized for acute heart failure. The study observed that patients receiving the medication showed better outcomes regarding death and heart failure events compared to those receiving a placebo.
The study evaluated a composite endpoint including all-cause mortality and heart failure events, as well as changes in symptom scores. While the results suggest a clear benefit, the study was limited to a 90-day follow-up period.
This research is significant because it explores whether SGLT2 inhibitors, which are known to help chronic heart failure patients, are also effective when treatment is started during an acute hospital stay.
Why it matters: Starting empagliflozin during acute heart failure hospitalization may improve clinical outcomes and is well tolerated.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
To cite this card, link to https://intellectplus.co.uk/app/health-research-empagliflozin-improves-clinical-outcomes-for-patients-hospit.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Heart & circulation · More in Health · Latest · A–Z · All topics
